Benralizumab is a medication that falls under the category of biologic drugs, specifically known as an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody. This medication is primarily used for the treatment of severe asthma in patients who have an eosinophilic phenotype.

Eosinophils are a type of white blood cell that plays a role in the inflammatory response in asthma. Benralizumab works by binding to the interleukin-5 receptor on the surface of eosinophils, leading to their destruction through a process called antibody-dependent cell-mediated cytotoxicity. By reducing the number of eosinophils in the body, Benralizumab helps to decrease inflammation in the airways and improve asthma symptoms.

Clinical studies have shown that Benralizumab can significantly reduce asthma exacerbations, improve lung function, and decrease the need for oral corticosteroids in patients with severe eosinophilic asthma. It is typically administered as a subcutaneous injection every 4 to 8 weeks, depending on the dosing regimen prescribed by your healthcare provider.

As with any medication, Benralizumab may cause side effects in some individuals. Common side effects may include injection site reactions, headache, and upper respiratory tract infections. It is important to discuss any concerns or potential side effects with your healthcare provider before starting treatment with Benralizumab.

Overall, Benralizumab is a valuable treatment option for patients with severe eosinophilic asthma who have not responded well to other asthma medications. If you have been diagnosed with severe asthma and have an eosinophilic phenotype, talk to your healthcare provider to see if Benralizumab may be a suitable treatment option for you.